Dianthus posts corporate presentation with Phase 3 CAPTIVATE interim data for claseprubart in CIDP

Dianthus Therapeutics, Inc. /DE/

Interim responder analysis data for first 40 patients from Part A of Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy.
Presentation posted on investor relations website on June 11, 2026.
No specific numeric results disclosed in the filing text; actual data is in the presentation slides.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.